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Abstract 
The primary goals of clinical research monitoring are to assure adequate 
protection of the rights of human subjects, and the safety of all subjects involved in 
clinical investigations or clinical trials, and the quality and integrity of the data generated 
from clinical trials. Adequate monitoring of clinical trials can prevent the occurrence of 
significant problems, which may affect the entire process of bringing a new drug to 
market. The proper monitoring of clinical trials is a challenge. In spite of well established 
regulations and guidance, there remain many monitoring related concerns in clinical trials 
(e.g. protocol deviations and violations, IRB violations, improper adverse event 
reporting, etc). The survey results indicate that clinical research coordinators believe that 
there are concerns in the monitoring process, and that the quality of monitoring varies 
from monitor to monitor. Results also suggest that some monitors are exceptional, where 
as some monitors are abysmal.  
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 Chapter 1: Introduction 
Clinical Research is a fast-growing, knowledge-based industry with a diverse pool of 
clinical research professionals (Gudadhe, 2001). Among the many professionals who play 
an important role in clinical research is the clinical monitor or clinical research associate 
(CRA). According to ICH GCP (1996), “Monitoring is the act of overseeing the progress 
of a clinical trial, and of ensuring that it is conducted, recorded, and reported in 
accordance with the protocol, standard operating procedures (SOPs), Good Clinical 
Practice (GCP), and the applicable regulatory requirement(s).” The monitor is the “first 
line of communication between the sponsor and the investigational site” (Nylen, 2000). 
According to ICH GCP (1996), the monitor is responsible for various activities such as:  
• Site selection. 
• Training the site staff. 
• Ensuring that the investigator and site staff are knowledgeable about the protocol 
and trial procedures.  
• Protecting the rights, safety, and well-being of human study subjects. 
• Checking the investigational product accountability. 
• Ensuring that the site is following the protocol properly. 
• Reviewing the CRFs, source documents, and informed consent documents. 
• Reviewing of serious adverse event reporting. 
• Helping the site staff in solving the generated queries. 
• Checking whether the investigator has essential documents for the conduct of a 
trial (i.e., review of proper documentation at the site). 
2 
 
• Informing the investigator about the deviations from protocol, SOPs, and GCP 
guidelines and taking appropriate action.  
Monitors should have scientific as well as clinical knowledge, and they should be 
trained adequately concerning the specifics of protocol which they are monitoring (ICH 
GCP, 1996). The quality of the clinical trial depends on the monitoring visit reports. Lack 
of proper monitoring may lead to many problems. Mihajlovic – Madzarevic (2010) 
identified the following problems which can result from inadequately performed 
monitoring: 
• Inability to determine whether there has been non – compliance, fraud or 
misconduct in the trial. 
• Failure to determine the CRF issues, protocol deviations, and violations. 
• Improper monitoring affecting subject safety and quality of data recorded in the 
trial. 
The monitor is appointed by a sponsor or a contract research organization to 
determine all the inconsistencies (e.g. Protocol deviations, CRF issues etc) in clinical 
trials (ICH GCP, 1996). According to Nylen (2000), ensuring proper and accurate 
adverse event reporting is one of the major responsibilities of the monitor. However, 
common findings from FDA inspections include improper adverse event reporting and 
failure to report adverse events to the FDA. Warning letters were issued to clinical 
investigators, sponsors, and contract research organizations for inadequate monitoring of 
clinical trials (Mihajlovic – Madzarevic, 2010). 
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Why are there inconsistencies, if there is a qualified, well-trained, knowledgeable, 
and experienced clinical monitor? (Inspection Observations, 2012). Why, then, are 
clinical monitors not able to determine the problems and facilitate their solution before 
the FDA identifies them? 
“The clinical research coordinator (CRC) is a specialized research professional 
working with, and under the direction of, the clinical investigator” (Woodin, 2009) and 
the responsibilities of clinical research coordinator are: 
• Reviewing and evaluating the protocol. 
• Screening and enrolling the study subjects. 
• Obtaining participant informed consent. 
• Protecting the rights, safety, and well-being of study subjects. 
• Ensuring that study medication was received by eligible subjects. 
• Completing all study documents at the study site properly. 
• Ensuring proper documentation at study site (e.g. Documenting signed informed 
consent forms). 
• Submitting all the essentials documents for IRB review. 
• Checking source documents and CRFs thoroughly. 
• Resolving data queries generated by monitor. 
• Proper scheduling of the study subject and monitor visits.  
The clinical research coordinator (CRC) plays an important role in study conduct. I 
have chosen clinical coordinators for this study, because the CRC is the person at the site 
who most frequently interacts with the monitor and will be able to comment most reliably 
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about the monitoring process (Wanna Be a Clinical Research Associate(CRA)? First 
Become a CRC!, n.d.). 
The current study focuses on the perceptions of clinical coordinators about the quality 
of monitoring. The information from this study will inform the identification of the major 
inadequacies in the monitoring process and the reasons underlying these inadequacies. 
These steps are crucial in developing strategies to improve the monitoring process and 
thereby improving the safety as well as the ethical and scientific quality of clinical 
research. 
 
 
 
 
 
 
 
 
 
5 
 
Chapter 2: Background 
According to the Bioresearch Monitoring Program report of 2011, a total of 127 cases 
with inconsistencies were reported in Sponsor/Monitor/CRO inspections (Bioresearch 
Monitoring (BIMO) Metrics – FY’11, 2011). The most common deficiencies found were: 
• Failure to report the protocol deviations in monitoring reports from one or more 
study sites. 
• Failure to report the informed consent violations in monitoring reports from one 
or more study sites. 
• Failure to report the IRB reporting violations in monitoring reports. 
• Continuous non-compliance regarding CRFs completion, review, and submission 
was determined by the sponsor through other means of communication, but 
monitoring reports does not include any of the issues regarding CRFs. 
• Failure to bring the investigators into compliance: 
• According to ICH GCP (1996), the monitor is responsible for ensuring 
that the investigator follows approved protocol and amendments (if any). 
If the investigator is not adhering to protocol, then it is (initially) the 
responsibility of the monitor to bring the investigator into compliance. 
However, warning letters were issued to investigators regarding non-
compliance in clinical trials. 
• Inadequate accountability for the investigational product (Bertram, 2002): 
• The monitor is responsible for ensuring accurate drug accountability at the 
investigational site i.e., monitors should review, documentation regarding 
drug accountability, ensure proper drug storage, and log maintenance during 
6 
 
monitoring visits. However, findings from the FDA include warning letters 
related to drug accountability (Drug Accountability at the Investigative site, 
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articl
eDetail.jsp?id=87219). 
• Failure to obtain FDA and IRB approval prior to study initiation: 
• According to ICH GCP (1996), the monitor is responsible for ensuring that 
the site has all required approvals before initiation of the study. However, 
there are FDA warning letters which cite that the monitor failed in 
determining non-compliance.  
All of the above are responsibilities of the monitor. In spite of well established 
regulations and guidance for monitoring, there are many concerns in clinical trials (e.g. 
protocol deviations and violations, IRB violations, improper adverse event reporting, etc). 
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Chapter 3: Thesis Statement 
 Purpose of the Study 
The purpose of the study is to determine the perceptions of clinical research 
coordinators about quality of monitoring and major inadequacies/concerns in the 
monitoring process. Hopefully, data collected will help the sponsors and monitors to 
develop solutions for the major concerns relating to the monitoring process.  
Research Questions 
Question 1: 
What are the perceptions of clinical research coordinators about the quality of 
monitoring? 
Question 2: 
What are the major concerns/failings in the monitoring process? 
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Chapter 4: Research Design and Methodology 
Target Population 
Target population refers to the entire group of people or objects or individuals to 
which the researcher generalizes the conclusions or study findings (Populations and 
Sampling, n.d.). It is also defined as a possible group of respondents to the survey 
questions. The target population for this study includes clinical research coordinators. 
Sample Population 
Sample population (Actual people or respondents selected for survey) is the subset 
of a target population and is also called a study population or sample size for the study 
(Populations and Sampling, n.d.). The sample population for this study includes 2177 
clinical research coordinators from different clinical research sites. 
Selection of Sample Size for Survey 
Sample size is determined by degree of precision (confidence interval) and 
accuracy (confidence level) required for the responses to the survey questions. For this 
study, confidence level is 95% and confidence interval is ±10%. Percentages below and 
above 50% would have the least amount of variance. Therefore, the sample for this study 
is based on a 50% point estimate for any question. Sample size needed to obtain the 
desired precision and accuracy is approximately 100 (Macorr research solutions, Sample 
size formula, http://www.macorr.com/sample-size-methodology.htm). Anticipating a 4% 
to 5% response rate, the survey was sent to 2177 research coordinators (Zoomerang 
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online surveys and polls, calculate survey sample size, 
http://www.zoomerang.com/sample-size/). 
Development of Survey Instrument or Questionnaire 
I performed the literature review and summarized the established concerns related 
to monitoring. Then I constituted a focus group with three members (Dr. Ronald Maio, 
Terry VandenBosch, and Ted Hamilton) at the University of Michigan and conducted 
focus group interactions. Then I developed the final questionnaire or survey instrument 
by using the suggestions from focus group participants. 
The questionnaire or survey questions include six general demographic questions 
(e.g. Academic degree, experience level), which provided the demographic information 
about coordinators and 15 questions related to monitoring practices (e.g. quality of 
monitoring, concerns in monitoring, importance of quality monitoring). 
General demographic questions are closed ended (multiple choice questions). 
Questions related to monitoring practices include both open ended and closed ended. I 
have used the five-point Likert rating scale for closed ended questions related to 
monitoring practices and open ended questions are to determine “what is at the tip of the 
respondent’s mind” (Brace, 2008). 
Human Subjects Protection 
Prior to conducting the research or study or survey, I submitted an application for 
Review and Approval to conduct research or a survey involving human subjects (Clinical 
Research Coordinators) to the College of Health and Human Services Human Subjects 
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Review Committee (CHHS-HSRC) at Eastern Michigan University. The CHHS-HSRC 
approved the study to conduct the survey on November 7, 2012. (Appendix A:  College 
of Health and Human Services Human Subjects Review Committee Approval Letter). 
All of the potential participants were informed clearly about the purpose of the 
study, procedure for responding to the survey, voluntariness and withdrawal, protecting 
the rights of the participant, and contact information by means of Online Survey Consent 
Form. (Appendix B: Survey Completion Request or Online Survey Consent Form or 
Email Survey). 
An Informed consent form or Online Survey Consent Form was mailed 
electronically along with the survey. By filling out the survey, the participant agreed to 
the conditions of Online Survey Consent Form. If the potential participants decided to 
participate, they were told that they could withdraw at anytime, and their participation 
was purely voluntary. There are no direct benefits or risks associated with their 
participation, and all the responses to the survey are anonymous and confidential. 
Method of Data Collection 
Finally, with the approval of the Human Subjects Review Committee (HSRC), I 
conducted the computer-based survey using Google docs. 
I (Investigator) emailed the survey instrument (Appendix C: Survey) including the 
email survey consent form to the potential participants following the approval of CHHS-
HSRC. The survey instrument included the consent form and three mandatory questions 
to be answered before they take the short online survey. The purpose of three mandatory 
questions is to ensure that the potential participant has read the consent form, voluntarily 
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agrees to take the survey, and participant is a clinical research coordinator (Survey should 
be taken only by the clinical research coordinators). Then, it directs the participant to the 
survey (Appendix C: Survey). After completing the six demographic questions and 15 
questions related to monitoring practices, the participant was directed to click the 
“submit” button, which submits their anonymous answers to the investigator.  
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Chapter 5: Analysis and Presentation of Data 
This chapter is dedicated to presentation of the results of the study which were 
obtained by analyzing the data of the responses received. 
The basis of this study is quantitative research acquired by collecting the 
perceptions of clinical research coordinators about the quality of monitoring through an 
electronic survey. The survey was emailed to 2177 potential participants along with a 
consent form stating that the survey was completely voluntary and their participation 
would remain anonymous. Out of the 2177 potential participants invited to participate in 
the study, 92 participants successfully completed the survey and submitted to the 
investigator, which represents a 4.23% response rate. Five participants did not meet the 
eligibility criteria because they are not clinical research coordinators, and their data or 
results were excluded from analysis. Therefore, 87 completed surveys were used in the 
final analysis of data. 
The electronic survey for this study evaluated the perceptions of clinical research 
coordinators about the quality of monitoring and major inadequacies or concerns in the 
monitoring process. 
Overview of Demographics 
The respondents were asked to answer six optional demographic questions before 
answering the monitoring practice questions. Demographic questions include their level 
of education, educational background, work setting, working pattern, experience as a 
clinical research coordinator, and experience in interacting with the monitors. Tables 1 to 
6 present the tabulations of the demographic responses. 
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Question 1:  
What is the highest degree (or) level of education you have completed? 
Survey respondents were asked to select from the following options: (a) High 
School Graduate, (b) Associate degree, (c) Bachelor’s degree, (d) Post-baccalaureate 
certificate, (e) Master’s degree, (f) Doctorate degree, (g) Other (Please Specify). 
The objective of this question was to evaluate whether a majority of the clinical 
research coordinators hold a master’s degree. 
As shown in Table 1, 42.5% of respondents hold a master’s degree, 41.4% of 
respondents hold a bachelor’s degree, 5.7% of respondents hold a doctorate degree, 5.7% 
of respondents hold a post baccalaureate certificate, 1.2% of respondents hold an 
associate degree, and 3.5% of respondents hold another degree like CFA. 
Question 2:  
Which of the following best describes your educational background? 
Survey respondents were asked to select from the following options: (a) Nursing 
degree, (b) Life Science degree (e.g. Pharmacy, Biochemistry, and Biology), (c) Health 
Science degree (e.g. Clinical Laboratory Science, Physical Therapy), (d) Clinical 
Research degree, (e) Other (Please Specify). 
The objective of this question was to evaluate whether a majority of the clinical 
research coordinators hold a clinical research degree. 
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As shown in Table 2, 28.7% of respondents have a life science degree like 
pharmacy, biochemistry, and biology, 21.8% of respondents have a health science degree 
like clinical laboratory science, and physical therapy, 23% of respondents have a nursing 
degree, 9.2% of respondents have a clinical research degree, and 17.3% of respondents 
have degrees in other fields like economics, social work, public health, statistics, 
psychology, and clinical social work. 
Question 3:  
Which of the following best describes your current work setting? 
Survey respondents were asked to select from the following options: (a) Private 
Practice site, (b) Academic site (University or Teaching Hospitals), (c) Community 
Hospital (Not Academically affiliated), (d) Site management organization (organizing a 
group of sites centrally to do studies), (e) Contract research organization (company or 
organization contracted by a pharmaceutical, medical device or biotechnology company 
to conduct clinical trials), (f) Other (please specify). 
The objective of this question was to evaluate in what kind of work setting or 
organization a majority of the clinical research coordinators are working. 
As shown in Table 3, 90.8% of respondents work at academic sites like university 
or teaching hospitals, 6.9% of respondents work at private practice sites, and 2.3% of 
respondents work at other work settings like non-profit genetic institutes, and community 
hospitals affiliated with an academic setting. 
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Question 4:  
Which of the following describes your current working pattern? (Select all that apply) 
Survey respondents were asked to select from the following options: (a) Medical 
device clinical trials, (b) Pharmaceutical clinical trials, (c) Investigator—initiated clinical 
trials, (d) Government (or) Foundation—sponsored clinical trials, (e) Other (please 
specify). 
The objective of this question was to evaluate whether a majority of the clinical 
research coordinators work on pharmaceutical clinical trials. 
As shown in Table 4, 37.1% of respondents work on investigator—initiated 
clinical trials, 26.9% of respondents work on government or foundation sponsored 
clinical trials, 24.6% of respondents work on pharmaceutical clinical trials, and 11.4% of 
respondents work on medical device clinical trials. 
Question 5:  
About how long have you been working as a clinical research coordinator? 
Survey respondents were asked to select from the following options: (a) ≤ 2 years, 
(b) > 2 to 5 years, (c) > 5 to 10 years, (d) > 10 years.  
The objective of this question was to evaluate the experience of clinical research 
coordinators. 
As shown in Table 5, 27.9% of respondents have more than 10 years of 
experience as a clinical research coordinator, 27.9% of respondents have 5 to 10 years, 
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27.9% of respondents have 2 to 5 years, and 16.3% of respondents have 0 to 2 years of 
experience as a clinical research coordinator. 
Question 6:  
How many clinical trials have you participated in where you have interacted with a 
monitor? 
Survey respondents were asked to select from the following options: (a) 1 to 5, (b) 
6 to 10, (c) 11 to 20, (d) > 20. 
The objective of this question was to evaluate the experience of clinical research 
coordinators with the clinical monitors. 
As shown in Table 6, 47.1% of respondents have participated in 1 to 5 trials 
where they interacted with the monitor, 23.5% of respondents have participated in more 
than 20 trials where they interacted with the monitor, 17.6% of respondents have 
participated in 6 to 10 clinical trials where they interacted with the monitor, and 11.8% of 
respondents have participated in 11 to 20 clinical trials where they interacted with the 
monitor. 
Overview of Responses or Reflections based on Monitoring Practice Questions 
The respondents were asked to answer 15 questions related to monitoring 
practices to evaluate the experiences of clinical research coordinators in relation to 
clinical monitoring. Tables 7 to 21 represent the reflections of clinical research 
coordinators about the monitoring process or practices. 
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Question 7:  
In general, how satisfied are you with the skill and competency of the monitors with 
whom you have interacted? 
Survey respondents were asked to select from the following options: (a) Very 
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied. 
The objective of this question was to evaluate what percentage of clinical 
monitors are knowledgeable to monitor the clinical trials. 
As shown in Table 7, 59.5% of respondents are satisfied with the skill and 
competency of monitors, 19.1% of respondents are not sure, 14.3% of respondents are 
very satisfied, and 7.1% of respondents are dissatisfied. 
Question 8:  
In general, how satisfied are you with the monitor’s level of understanding of the 
protocol and its requirements? 
Survey respondents were asked to select from the following options: (a) Very 
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied. 
The objective of this question was to evaluate what percentage of monitors are 
familiar with the clinical trial protocol and protocol amendments because protocol is the 
most important document which is the basis for clinical trial monitoring. 
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As shown in Table 8, 60.7% of respondents were satisfied with the monitors 
understanding of protocol and its requirements, 21.4% of respondents were very satisfied, 
11.9 % of respondents were not sure, and 6.0% of respondents were dissatisfied. 
Question 9:  
In general, how satisfied are you with the review of the informed consent process 
conducted by the monitors with whom you have interacted? 
Survey respondents were asked to select from the following options: (a) Very 
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied. 
The objective of this question was to evaluate to what extent the monitors are 
reviewing proper completion and documentation of informed consent process because 
informed consent process is the keystone for conducting the research or clinical trial or 
clinical study ethically. 
As shown in Table 9, 54.8% of respondents were satisfied with the monitors 
review of informed consent process, 22.6% of respondents were very satisfied, 19.0% of 
respondents were not sure, and 3.6% of respondents were dissatisfied. 
Question 10:  
In general, how satisfied are you with the review for protocol deviations conducted by the 
monitors with whom you have interacted? 
Survey respondents were asked to select from the following options: (a) Very 
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied. 
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The objective of this question was to evaluate whether the monitors are properly 
reviewing the protocol deviations in their monitoring visits and discussing about the 
issues with the clinical research or trial coordinators for remedial action. Protocol 
deviations may affect the patient safety, and quality of data recorded during the trial. 
As shown in Table 10, 52.4% of respondents were satisfied with the monitors 
review for protocol deviations, 17.9% of respondents were very satisfied, 19.0% of 
respondents were not sure, and 10.7% of respondents were dissatisfied. 
Question 11:  
In general, how satisfied are you with the review for accuracy and completeness of CRF 
entries and source documents against each other conducted by the monitors with whom 
you have interacted? 
Survey respondents were asked to select from the following options: (a) Very 
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied. 
The objective of this question was to evaluate what percentage of monitors are 
detail oriented and comparing the data in the CRF’s with the source documents properly. 
This process is very important because it investigates whether reliable, and accurate 
information is being reported in the study or not.  
As shown in Table 11, 55.9% of respondents were satisfied with the monitors 
review for accuracy and completeness of CRF’s against source documents, 22.6% of 
respondents were very satisfied, 14.3% of respondents were not sure, 6.0% of 
respondents were dissatisfied, and1.2 % of respondents were very dissatisfied. 
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Question 12:  
In general, how satisfied are you with the review for reporting of adverse events 
conducted by the monitors with whom you have interacted? 
Survey respondents were asked to select from the following options: (a) Very 
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied. 
The objective of this question was to evaluate whether monitors are checking the 
proper reporting of adverse events and assisting the trial coordinators in correctly 
reporting the adverse events. Proper reporting of adverse events is very important in 
ensuring the patient safety. 
As shown in Table 12, 60.2% of respondents were satisfied with the monitors 
review of adverse events, 19.3% of respondents were very satisfied, 12.1% of 
respondents were not sure, and 8.4% of respondents were dissatisfied. 
Question 13:  
In general, how satisfied are you with the review for accuracy of drug accountability 
records conducted by the monitors with whom you have interacted? 
Survey respondents were asked to select from the following options: (a) Very 
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied. 
The objective of this question was to evaluate whether monitors are properly 
reviewing the drug accountability records to ensure the quality and accuracy of drug 
accountability during the course of a trial. Improper drug accountability may affect the 
outcome of a clinical trial. 
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As shown in Table 13, 53.8% of respondents were satisfied with the monitors 
review for accuracy of drug accountability records, 23.7% of respondents were very 
satisfied, and 22.5% of respondents were not sure. 
Question 14:  
In general, how likely are the monitors with whom you have interacted to fail to review 
FDA and IRB approvals prior to study initiation?  
Survey respondents were asked to select from the following options: (a) Very 
Likely, (b) Likely, (c) Not sure, (d) Unlikely, (e) Very Unlikely. 
The objective of this question was to evaluate whether monitors are reviewing 
required approvals for study initiation because protection of patients is very important in 
clinical trials. 
As shown in Table 14, 32.2% of respondents indicate that very unlikely monitor’s 
fail to review the FDA and IRB approvals prior to study initiation, 29.8% of respondents 
indicate unlikely, 22.6% of respondents are not sure, 8.3% of respondents indicate likely, 
and 7.1% of respondents indicate very likely. 
Question 15:  
In general, how likely are the monitors with whom you have interacted to provide 
adequate technical support to the site staff about the study?  
Survey respondents were asked to select from the following options: (a) Very 
Likely, (b) Likely, (c) Not sure, (d) Unlikely, (e) Very Unlikely. 
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The objective of this question was to evaluate whether monitors are supporting 
and helping the site staff during the course of a clinical trial. 
As shown in Table 15, 47.6 % of respondents indicate that the monitors likely 
provide the technical support, 20.7% of respondents indicate very likely, 17.1% of 
respondents were not sure, 12.2% of respondents indicate unlikely, and 2.4% of 
respondents indicate very unlikely. 
Question 16:  
In general, how likely are the monitors with whom you have interacted to help the site 
staff in resolving the generated queries? 
Survey respondents were asked to select from the following options: (a) Very 
Likely, (b) Likely, (c) Not sure, (d) Unlikely, (e) Very Unlikely. 
The objective of this question was to evaluate whether monitors are helping the 
site staff in addressing the queries properly and resolving them. 
As shown in Table 16, 50.0% of respondents believe that monitors likely help the 
site staff in resolving the queries, 32.1% of respondents believe that very likely monitors 
help the site staff in resolving queries, 10.7% of respondents believe that unlikely 
monitors help the site staff in resolving the queries, and 7.2% of respondents were not 
sure. 
Question 17:  
In general, how likely are the monitors with whom you have interacted to provide site 
monitoring reports in a short time frame after completing a monitoring visit? 
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Survey respondents were asked to select from the following options: (a) Very 
Likely, (b) Likely, (c) Not sure, (d) Unlikely, (e) Very Unlikely. 
The objective of this question was to evaluate whether the monitors are providing 
the monitoring reports within the time frame stating any issues that were observed during 
monitoring inspection. Monitoring reports are very helpful in addressing the issues during 
the study and ensure the progress of a clinical trial. 
As shown in Table 17, 54.9% of respondents believe that monitors likely provide 
the monitoring report within short time frame, 18.3% of respondents believe very likely 
to provide the monitoring report within short time frame, 14.6% of respondents were not 
sure, 11.0% of respondents indicate that monitors unlikely provide the monitoring report 
within the short time frame, and 1.2% of respondents indicate that very unlikely monitors 
provide the monitoring report within the short time frame. 
Question 18:  
In general, how likely is it that there is an increase in work load following the completion 
of a monitoring visit? 
Survey respondents were asked to select from the following options: (a) Very 
Likely, (b) Likely, (c) Not sure, (d) Unlikely, (e) Very Unlikely. 
The objective of this question was to evaluate whether the monitors are increasing 
the workload of the site staff due monitoring visit or helping the site staff in addressing 
the issues properly in turn decreasing the workload of clinical research coordinators. 
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As shown in Table 18, 42.2% of respondents reveal that monitors likely increase 
the work load after the monitoring visit, 36.1% indicate very likely, 12.0% represent 
unlikely, and 9.7% of respondents are not sure. 
Question 19:  
In general, in a clinical study, how much do you believe the quality of the data at your 
site reflects upon the monitors with whom you have interacted? 
Survey respondents were asked to select from the following options: (a) Very 
much, (b) Moderately, (c) Not sure, (d) Minimally, (e) Does not reflect. 
The objective of this question was to evaluate whether the quality of data and 
success of a clinical trial will depend on the monitor or not. 
As shown in Table 19, 39.8% of respondents believe quality of data depends 
moderately upon monitor, 27.7% of respondents believe that quality of data depends very 
much upon monitor, 16.9% of respondents are not sure, and15.6 % of respondents 
believe that quality of data minimally depends upon monitor. 
Question 20:  
Has your site been audited or inspected in the past 3 years?  If so, has the monitor been 
helpful in preparation for the audit or inspection? 
Survey respondents were asked to select from the following options: (a) Very 
much, (b) Moderately, (c) Not sure, (d) Minimally, (e) Not at all. 
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The objective of this question was to evaluate whether the monitor is helping the 
site staff in reporting the accurate data according to the protocol, SOP’s, GCP’s and 
applicable regulatory requirements. A clinical trial audit is necessary to protect the 
subjects and to ensure that the trail is conducted according to the required regulations. 
As shown in Table 20, 37.5% of respondents are not sure about the monitors help 
in the preparation of audit or inspection, 27.8% of respondents believe that monitor was 
helpful moderately in the preparation for the audit, 13.9% of respondents indicate that 
monitor was not at all helpful in the preparation for the audit or inspection, 12.5% of 
respondents reveal that monitor was very much helpful, and 8.3% of respondents believe 
that monitor was minimally helpful. 
Question 21:  
In general, what is your opinion about the quality of monitoring in clinical trials today as 
compared to 5-10 years ago? 
The objective of this question was to evaluate whether the quality monitoring was 
increasing day by day or decreasing. 
This is an open ended question, and respondents were allowed to write their own 
comments about the quality of monitoring. The responses to this question were tabulated 
in Table 21. 
Summary of Results/Findings based on the Data Collected 
• 42.5% of the clinical research coordinators who responded hold a master’s 
degree. 
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• 9.2% of clinical research coordinators who responded have a clinical research 
degree and that the majority of the clinical research coordinators have a degree in 
a life science, e.g. pharmacy, bio-chemistry and biology. 
• 90.8% of the clinical research coordinators who responded work at sites which are 
affiliated with a university or teaching hospital. 
• 37.1% of the clinical research coordinators who responded are working on 
investigator-initiated clinical trials. 
• 83.7% of respondents have more than two years of experience as a clinical 
research coordinator. 
• 47.1% of the clinical research coordinators who responded have participated in at 
least one clinical trial where they have interacted with a monitor. 
• Only 14.3% of the clinical research coordinators who responded were very 
satisfied with the monitors who visited them, but most (59.5%) of the clinical 
research coordinators were satisfied with the skill and competency of the monitors 
with whom they have interacted. 
• Only 21.4% of clinical research coordinators who responded were very satisfied, 
and most (60.7%) of the clinical research coordinators were satisfied with the 
monitor’s level of understanding of the protocol and its requirements. 
• 22.6% of the clinical research coordinators who responded were very satisfied, 
and 54.8% of the clinical research coordinators were satisfied with the review of 
the informed consent process conducted by the monitors with whom they have 
interacted. 
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• 17.9% of the clinical research coordinators who responded were very satisfied, 
and more than half (52.4%) of the clinical research coordinators were satisfied 
with the review for protocol deviations conducted by the monitors with whom 
they have interacted. 
• 22.6% of the clinical research coordinators who responded were very satisfied, 
whereas 55.9% of clinical research coordinators were satisfied with the monitors 
review for the accuracy and completeness of CRF’s and source documents. 
• Only 19.3% of the clinical research coordinators who responded were very 
satisfied, and 60.2% of the clinical research coordinators were satisfied with the 
monitors review for reporting of adverse events. 
• 23.7% of the clinical research coordinators who responded were very satisfied, 
and 53.8% were satisfied with the monitors review for accuracy of drug 
accountability records. 
• 29.8% of the clinical research coordinators who responded indicated unlikely, 
whereas 32.2% of clinical research coordinators indicate that it is very unlikely 
that monitors fail to review the FDA and IRB approvals prior to study initiation. 
• 20.7 % of the clinical research coordinators who responded indicated that the 
monitor is very likely to provide the technical support (e.g. helping site staff in 
resolving the enrollment barrier, training the site staff, and helping the site staff in 
resolving the issues encountered during the conduct of the study), and 47.6% of 
respondents indicate that the monitors likely provide the technical support. 
• 50.0% of the clinical research coordinators who responded indicated that the 
monitors are likely to help the site staff in resolving the generated queries, 
28 
 
whereas 32.1% of clinical research coordinators indicated that it is very likely that 
monitors help the site staff in resolving queries. 
• 54.9% of the clinical research coordinators who responded indicated that the 
monitors are likely to provide the monitoring report within a short time after the 
visit, and 18.3% of clinical research coordinators indicated that the monitors are 
very likely to provide the monitoring report within a short time after the visit. 
• 88.0% of the clinical research coordinators who responded indicated that the 
monitors are likely to increase the work load after the completion of a monitoring 
visit. 
• 27.7% of the clinical research coordinators who responded believe that the quality 
of trial data depends very much upon the monitor, and 39.8% of the clinical 
research coordinators believe that the quality of trial data depends moderately 
upon the monitor. 
• 12.5% of respondents indicated that the monitor was very much helpful, and 
27.8% of respondents believe that monitor was moderately helpful in the 
preparation for an audit or inspection of the site. 
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Chapter 6: Summary, Conclusion, and Inferences 
The objective of this study was to determine the perceptions of the clinical 
research coordinators about the quality of clinical monitoring. The author of this report 
thinks that there are some problems in the monitoring of clinical trials based on the 
warning letters issued to clinical investigators, sponsors, and CROs for inadequate 
monitoring of clinical trials. Therefore, he is interested in finding the reasons for 
improper monitoring and major concerns in the monitoring process as well as perceptions 
of clinical research coordinators about the quality of monitoring. 
The data from this study suggest that there are issues or problems in the 
monitoring of clinical trials based on the perceptions of clinical research coordinators. 
This study found that majority of the clinical research coordinators participating 
in the study have either a master’s degree or bachelor’s degree in life science (pharmacy, 
biology, and bio-chemistry) or nursing, majority are working at academic sites like 
university or teaching hospitals, and the majority participated in all kinds of clinical trials 
like medical device clinical trials, pharmaceutical clinical trials, investigator-initiated 
clinical trials, and government or foundation sponsored clinical trials. Also, a majority of 
the clinical research coordinators participating in this study have more than 2 years of 
experience in clinical trials and have interacted with the monitor in at least one clinical 
trial.  Results also indicate that very few of the clinical research coordinators have a 
clinical research degree. 
Based on the responses to the monitoring practice questions, majority of the 
clinical research coordinators are satisfied with the skill and competency of monitors, the 
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monitor’s level of understanding of the protocol and its requirements, the monitor’s 
review for the informed consent process violations, the monitor’s review for the protocol 
deviations, the monitor’s review for accuracy and completeness of CRF’s (case report 
form) as well as source documents, the monitor’s review for proper reporting of adverse 
events, and the monitor’s review for accuracy of drug accountability records. They also 
indicate that the monitors review the IRB and FDA approvals before the study initiation, 
provide adequate technical support to the site staff about the study and also the 
monitoring reports within a short time frame, and help the site staff in resolving the 
generated queries and also in the preparation of the site for audits or inspections. Results 
also reveal that most of the clinical research coordinators believe that the quality of data 
in a clinical trial depends upon the monitor. 
On the other hand, a majority of the clinical research coordinators participated in 
this study stated that the monitors are increasing the workload after the completion of a 
monitoring visit. Although a majority of the coordinators are satisfied with the work done 
by the monitors, some of the clinical research coordinators are not satisfied with the skill 
of monitors, the monitor’s protocol knowledge, and the monitor’s review for the 
problems in the informed consent process as well as with the monitor’s review for 
protocol deviations. Also, they are not satisfied with the monitor’s review for accuracy 
and completeness of CRF’s as well as the source documents review, review for proper 
reporting of adverse events. They also state that the monitors fail to review the required 
approvals before the study initiation, do not provide the adequate technical support for 
the study, do not help the site staff in resolving the generated queries as well as in the 
preparation of the site for audits or inspections, and will not provide the monitoring visit 
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report quickly or within the time frame. Very few clinical research coordinators believe 
that the quality of data minimally depends upon the monitor. 
Major Concerns or Problems in the Monitoring Process 
Following are the major concerns or problems in the monitoring process based on the 
percent of response by the clinical research coordinators: 
• Monitors are increasing the work load on clinical research coordinators after the 
monitoring visit. 
• Monitors failed to review the required approvals like FDA and IRB approvals 
prior to the study initiation. 
• Monitors failed to provide the technical support to the site staff during the course 
of a clinical trial. 
• Monitors are not providing the support to the site staff in the preparation of the 
site for the inspection or audit. 
• Monitors are not providing the monitoring visit reports within a short time frame. 
• Monitors failed to review the protocol deviations properly. 
• Monitors are not supporting or helping the site staff properly in the process of 
solving the generated queries. 
• Monitors failed to review the proper reporting of adverse events. 
• Monitors failed to review the accuracy as well as the completeness of CRF’s and 
source documents. 
• Some monitors do not have the required skills and knowledge. 
• Monitors do not have the required protocol knowledge. 
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• Monitors failed to review the informed consent process properly. 
Clinical Research Coordinators Perceptions about the Quality of Monitoring 
  Perceptions of clinical research coordinators about the quality of monitoring are 
quite variable. Based on the responses given to the open-ended question about quality of 
monitoring, some clinical research coordinators believe that the quality of monitoring has 
increased compared to the monitoring five to ten years ago. Some clinical research 
coordinators believe that there is minimal improvement in monitoring and some other 
coordinators believe that there is no significant change in the quality of monitoring. But 
the majority of the clinical research coordinators conclude that the overall quality of the 
clinical monitoring has decreased. 
Perhaps the study coordinator’s perceived quality of monitoring varies from 
monitor to monitor because some clinical research associates are trained well and they 
have good knowledge about the study as well as about the applicable regulations. Also, 
perhaps perceptions could be affected by the fact that some clinical research coordinators 
have positive experience with the monitors, whereas some clinical research coordinators 
have a hard time in working with the monitors.  
Reasons for Decreased Quality of Monitoring 
Based on the findings of this study, the author suggests the following: 
• Monitors are not trained or mentored well. 
• Monitors have inadequate knowledge. 
• Monitors have a lack of adequate experience as a clinical research associate. 
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• Monitors were changed during the course of the study. 
• Monitors are overwhelmed with too many sites or too many studies. 
How Can we Improve the Quality of Monitoring? 
The quality of monitoring can be improved by training the clinical research 
associates adequately according to the industry standards, which in turn depends on the 
CROs, sponsors, or monitoring company for which the monitors are working. Skills of 
the clinical trial monitors can also be improved by encouraging them to attend the 
conferences related to clinical monitoring. 
Clinical monitors should be trained in such a way that the monitors have a good 
understanding of the protocol as well as the SOPs related to the study on which they will 
be working (SPONSOR, n.d). Clinical monitors need to have the appropriate and 
adequate clinical knowledge as well as scientific knowledge required to monitor the 
clinical trials adequately (ICH GCP, 1996). Proper planning by the monitors can also 
help in reflecting quality data (The art and science of monitoring, 2001). 
Decrease the workload of the clinical monitors, which can be done by decreasing 
the number of protocols or studies or sites they are responsible for monitoring and also by 
increasing the number of clinical monitors for the purpose of monitoring the studies 
(Kenneth, 2012). Have the same monitor for the study until the study closes. If the 
monitors change frequently during the study, it disturbs the way the study is done and the 
quality of monitoring decreases. It also decreases the proper communication between the 
site staff and monitors. Improve the communication power or capability of clinical 
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monitors with other the monitors, sponsors, investigators as well as with the site staff 
during the conduct of the clinical trial (The art and science of monitoring, 2001). 
Implementation of the correct monitoring procedures increases quality of monitoring. 
The quality of monitoring can also be increased by hiring the monitors with required 
qualifications as well as with the adequate experience in the monitoring or as a clinical 
research coordinator. Prior experience as a clinical research coordinator enables the 
monitors to efficiently find and help in correcting the problems (Wanna Be a Clinical 
Research Associate [CRA]? First Become a CRC!, n.d.). 
Finally, through excellent coordination and team work we can improve the quality 
of monitoring as well as quality of data reflected in the clinical trials, which paves a path 
for the success of a clinical trial. 
Conclusion 
This research study suggests that there are still concerns about the monitoring 
process, which affect the quality of monitoring, which in turn which may have impact on 
the quality of data reflected in the study as well as on the success of a clinical trial. 
Effective monitoring can be achieved by addressing the issues in the process of 
monitoring through which we can protect the subjects as well as improve the health of 
subjects. 
Effective clinical monitoring ensures that the clinical trial is conducted, recorded, 
and reported in accordance with the protocol’s standard operating procedures (SOPs), 
good clinical practice (GCP), and the applicable regulatory requirement(s), which dictates 
that the clinical trials should be conducted according to the ethical principles necessary 
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for the proper conduct of a clinical trial. This can be achieved through qualified, 
competent, and knowledgeable monitors.  
Monitors should be trained effectively, as they are ultimately responsible for the 
success of a clinical trial. Monitors should be knowledgeable about the trial documents, 
clinical or study protocol, Good Clinical Practice (GCP), Standard Operating Procedures 
(SOPs), local and state laws and other applicable regulations, research ethics and study 
conduct issues, and the ethical issues that they may encounter during conduct of a clinical 
trial.  
Monitors should be proficient in finding the concerns related to the approved 
protocol, informed consent documents as well as the process, SOPs, reporting of adverse 
events, participant’s inclusion criteria for the study, clinical trial documentation, and site 
facilities. Also monitors have to check whether the investigators and the study team are 
qualified and knowledgeable. The monitor is also responsible for ensuring whether 
participant confidentiality is maintained. 
Responsible clinical monitoring ensures the protection of participants and their 
rights while meeting the GCP standards and regulations and properly following the 
protocol and SOPs. An effective clinical monitor is responsible for finding the problems 
in the study as well as with the data recorded in the trial and ensuring the compliance as 
well as the progress of a clinical trial. Success of the research project or clinical trial or 
study depends on choosing the right trained, knowledgeable, and experienced monitoring 
team. 
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In summary, the monitor is responsible for the successful execution of a clinical 
study. By strengthening the communication between the site staff and the monitor, clean 
and quality data can be acquired by following the applicable regulations as well as 
protecting the rights and safety of participants or subjects. Monitors’ roles are very 
valuable because they help in guiding the new medications to the market and directly 
affect the health of the participants around the country as well as at the global level. 
Limitations and Recommendations for Future Research 
There are some limitations for this study. First, the overall response rate was only 
4.23%. Second, the sample of this study is limited to clinical research coordinators, and 
most of the respondents were working at sites which are affiliated with a university or a 
teaching hospital. Also, the respondents are primarily working on the investigator-
initiated clinical trials. Therefore, my responding sample may not be representative, and 
the results of this study are limited to the perceptions and experiences of the sample 
group. 
Through this study, the author has provided evidence to suggest that there are still 
concerns in clinical monitoring despite the presence of the well established regulations 
for monitoring practice. A similar study can be done or replicated with a larger sample, 
which would enhance the validity and reliability of the conclusions reached. This study 
captured and examined only the perceptions of clinical research coordinators, which is a 
select population. A more broad population of clinical research professionals would 
likely provide wide range of monitoring practice concerns as well as wide range of 
perceptions about the quality of monitoring. 
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Demographic Profile of Clinical Research Coordinators 
Table 1 
Survey Respondents by the Level of Education they have completed 
Response or Answer  Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
High School Graduate 
 
 
0 
 
 
0% 
 
 
0 
 
 
0% 
 
Associate degree 
 
1 
 
1.2% 
 
1 
 
1.2% 
 
Bachelor’s degree 
 
36 
 
41.4% 
 
37 
 
42.6% 
 
Post-baccalaureate certificate 
 
5 
 
5.7% 
 
42 
 
48.3% 
 
Master’s degree 
 
37 
 
42.5% 
 
79 
 
90.8% 
 
Doctorate degree 
 
5 
 
5.7% 
 
84 
 
96.5% 
 
Other 3 
 
 
3.5% 87 100.0% 
 
  TOTAL 87 100%   
 
 
Figure 1. Highest Degree or Level of Education Completed by Clinical Research 
Coordinators 
0% 1.20%
41.40%
5.70%
42.50%
5.70% 3.50%
0%
10%
20%
30%
40%
50%
Education Level
41 
 
Table 2 
Survey Respondents based on their Educational Background 
Response or Answer Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Nursing degree 
 
 
20 
 
 
23% 
 
 
20 
 
 
23% 
 
Life Science degree  
(e.g. Pharmacy,  
Biochemistry,  
Biology) 
 
25 
 
 
 
 
28.7% 
 
 
 
 
45 
 
 
 
 
51.7% 
 
 
 
 
Health Science degree  
(e.g. Clinical  
Laboratory Science,  
Physical Therapy) 
 
19 
 
 
 
 
21.8% 
 
 
 
 
64 
 
 
 
 
73.5% 
 
 
 
 
Clinical Research degree 
 
8 
 
9.2% 
 
72 
 
82.7% 
 
Other 
 
15 
 
17.3% 87 100.0% 
  TOTAL 87 100%   
 
 
Figure 2. Educational Background of Clinical Research Coordinators 
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Table 3 
Survey Respondents based on their Current Work Setting 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Private Practice site 
 
 
6 
 
 
6.9% 
 
 
6 
 
 
6.9% 
 
Academic site  
(University or  
Teaching Hospitals) 
79 
 
 
90.8% 
 
 
85 
 
 
97.7% 
 
 
 
Community Hospital  
(Not Academically 
affiliated) 
 
 
0 
 
 
 
0% 
 
 
 
85 
 
 
 
97.7% 
 
 
Site management 
organization  
 
0 
 
0% 
 
85 
 
97.7% 
 
Contract research 
organization  
 
 
0 
 
 
0% 
 
 
85 
 
 
97.7% 
 
 
Other 
 
2 2.3% 
 
87 100.0% 
  TOTAL 87 100%   
 
 
Figure 3. Work Setting of the Clinical Research Coordinators 
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Table 4 
Survey Respondents based on their Current Working Pattern 
Response or Answer  Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Medical device  
clinical trials 
 
 
19 
 
 
 
11.4% 
 
 
 
19 
 
 
 
11.4% 
 
 
Pharmaceutical  
clinical trials 
 
41 
 
 
24.6% 
 
 
60 
 
 
36.0% 
 
 
Investigator - initiated  
clinical trials 
 
62 
 
 
37.1% 
 
 
122 
 
 
73.1% 
 
 
Government (or)  
Foundation – sponsored  
clinical trials 
 
45 
 
 
 
26.9% 
 
 
 
167 
 
 
 
100.0% 
 
 
 
Other 
 
0 0% 167 100.0% 
  TOTAL 167 100%   
                            People may select more than one check box or response, that’s why 
respondents number (N=167) is more than 87 (number of people actually responded). 
 
Figure 4. Working Pattern of Clinical Research Coordinators 
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Table 5  
Survey Respondents based on their Experience as a Clinical Research Coordinator 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
≤ 2 years 
 
 
14 
 
 
16.3% 
 
 
14 
 
 
16.3% 
 
> 2 to 5 years 
 
24 
 
27.9% 
 
38 
 
44.2% 
 
> 5 to 10 years 
 
24 
 
27.9% 
 
62 
 
72.1% 
 
> 10 years 24 27.9% 86 100.0% 
   TOTAL 86 100%   
 
 
Figure 5. Experience of Clinical Research Coordinators 
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Table 6  
Survey Respondents based on their Experience with the Clinical Monitor 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
1 to 5 
 
40 
 
47.1% 
 
40 
 
47.1% 
 
6 to 10 
 
 
15 
 
 
17.6% 
 
 
55 
 
 
64.7% 
 
11 to 20 
 
10 
 
11.8% 
 
65 
 
76.5% 
 
> 20 
 
20 23.5% 85 100.0% 
   TOTAL 85 100%   
 
 
Figure 6. Number of Clinical Trials Interacted With Monitor 
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Presentation of Responses to Monitoring Practice Questions 
Table 7  
Survey Respondents based on their Satisfaction with the Skill as well as Competency of 
the Monitors 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very satisfied 
 
 
12 
 
 
14.3% 
 
 
12 
 
 
14.3% 
 
Satisfied 
 
50 
 
59.5% 
 
62 
 
73.8% 
 
Not sure 
 
16 
 
19.1% 
 
78 
 
92.9% 
 
Dissatisfied 
 
6 
 
7.1% 
 
84 
 
100.0% 
 
Very dissatisfied 
 
0 0% 84 100.0% 
   TOTAL 84 100%   
 
 
Figure 7. Satisfaction of Clinical Research Coordinators with the Skill and Competency 
of Monitors 
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Table 8  
Survey Respondents based on their Satisfaction with the Monitor’s Knowledge about 
Protocol and Its Requirements 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very satisfied 
 
 
18 
 
 
21.4% 
 
 
18 
 
 
21.4% 
 
Satisfied 
 
51 
 
60.7% 
 
69 
 
82.1% 
 
Not sure 
 
10 
 
11.9% 
 
79 
 
94.0% 
 
Dissatisfied 
 
5 
 
6.0% 
 
84 
 
100.0% 
 
Very dissatisfied 
 
0 0% 84 100.0% 
   TOTAL 84 100%   
 
 
Figure 8. Satisfaction of Clinical Research Coordinators with the Monitor’s 
Understanding of Protocol and Its Requirements 
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Table 9  
Survey Respondents based on their Satisfaction with the Review for Informed Violations 
by the Monitors 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very satisfied 
 
 
19 
 
 
22.6% 
 
 
19 
 
 
22.6% 
 
Satisfied 
 
46 
 
54.8% 
 
65 
 
77.4% 
 
Not sure 
 
16 
 
19.0% 
 
81 
 
96.4% 
 
Dissatisfied 
 
3 
 
3.6% 
 
84 
 
100.0% 
 
Very dissatisfied 
 
0 0% 84 100.0% 
   TOTAL     
 
 
Figure 9. Satisfaction of Clinical Research Coordinators with the Monitor’s Review of 
Informed Consent Process 
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Table 10 
Survey Respondents based on the Satisfaction with the Review for Protocol Deviations by 
the Monitors 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very satisfied 
 
 
15 
 
 
17.9% 
 
 
15 
 
 
17.9% 
 
Satisfied 
 
44 
 
52.4% 
 
59 
 
70.3% 
 
Not sure 
 
16 
 
19.0% 
 
75 
 
89.3% 
 
Dissatisfied 
 
9 
 
10.7% 
 
84 
 
100.0% 
 
Very dissatisfied 
 
0 0.0% 84 100.0% 
   TOTAL 84 100%   
 
 
Figure 10. Satisfaction of Clinical Research Coordinators with the Monitor’s Review for 
Protocol Deviations 
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Table 11  
Survey Respondents based on their Satisfaction with the Review for Accuracy of CRF’s 
and Source Documents by the Monitors 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very satisfied 
 
 
19 
 
 
22.6% 
 
 
19 
 
 
22.6% 
 
Satisfied 
 
47 
 
55.9% 
 
66 
 
78.5% 
 
Not sure 
 
12 
 
14.3% 
 
78 
 
92.8% 
 
Dissatisfied 
 
5 
 
6.0% 
 
83 
 
98.8% 
 
Very dissatisfied 
 
1 1.2% 84 100.0% 
   TOTAL 84 100%   
 
 
Figure 11. Satisfaction of Clinical Research Coordinators with the Monitor’s Review for 
Accuracy and Completeness of CRF’s, Source Documents and against Each Other 
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Table 12  
Survey Respondents based on their Satisfaction with the Review for Reporting of Adverse 
Events by the Monitors 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very satisfied 
 
 
16 
 
 
19.3% 
 
 
16 
 
 
19.3% 
 
Satisfied 
 
50 
 
60.2% 
 
66 
 
79.5% 
 
Not sure 
 
10 
 
12.1% 
 
76 
 
91.6% 
 
Dissatisfied 
 
7 
 
8.4% 
 
83 
 
100.0% 
 
Very dissatisfied 
 
0 0.0% 83 100.0% 
   TOTAL 83 100%   
 
 
Figure 12. Satisfaction of Clinical Research Coordinators with the Monitor’s Review of 
Adverse Events 
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Table 13 
Survey Respondents based on their Satisfaction with the Review for Accuracy of Drug 
Accountability Records by the Monitors 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very satisfied 
 
 
19 
 
 
23.7% 
 
 
19 
 
 
23.7% 
 
Satisfied 
 
43 
 
53.8% 
 
62 
 
77.5% 
 
Not sure 
 
18 
 
22.5% 
 
80 
 
100.0% 
 
Dissatisfied 
 
0 
 
0.0% 
 
80 
 
100.0% 
 
Very dissatisfied 
 
0 0.0% 80 100.0% 
   TOTAL 80 100%   
 
 
Figure 13. Satisfaction of Clinical Research Coordinators with the Monitor’s Review of 
Drug Accountability Records for Accuracy 
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Table 14  
Survey Respondents based on their Opinion about the Likeliness of Monitors Failing to 
Review the Required Approvals Prior to Study Initiation 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very Likely 
 
 
6 
 
 
7.1% 
 
 
6 
 
 
7.1% 
 
Likely 
 
7 
 
8.3% 
 
13 
 
15.4% 
 
Not sure 
 
19 
 
22.6% 
 
32 
 
38.0% 
 
Unlikely 
 
25 
 
29.8% 
 
57 
 
67.8% 
 
Very Unlikely 
 
27 32.2% 84 100.0% 
   TOTAL 84 100%   
 
 
Figure 14. Likeliness of Monitor Fails To Review IRB and FDA Approvals 
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Table 15  
Survey Respondents based on their Judgment about the Likeliness of Monitors Providing 
Required Technical Support to the Site Staff 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very Likely 
 
 
17 
 
 
20.7% 
 
 
17 
 
 
20.7% 
 
Likely 
 
39 
 
47.6% 
 
56 
 
68.3% 
 
Not sure 
 
14 
 
17.1% 
 
70 
 
85.4% 
 
Unlikely 
 
10 
 
12.2% 
 
80 
 
97.6% 
 
Very Unlikely 
 
2 2.4% 82 100.0% 
   TOTAL 82 100%   
 
 
Figure 15. Likeliness of Technical Support Provided by Monitor’s to Clinical Research 
Coordinators 
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Table 16  
Survey Respondents based on their View about the Likeliness of Monitors Helping the 
Site Staff in Resolving the Generated Queries 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very Likely 
 
 
27 
 
 
32.1% 
 
 
27 
 
 
32.1% 
 
Likely 
 
42 
 
50.0% 
 
69 
 
82.1% 
 
Not sure 
 
6 
 
7.2% 
 
75 
 
89.3% 
 
Unlikely 
 
9 
 
10.7% 
 
84 
 
100.0% 
 
Very Unlikely 
 
0 0.0% 84 100.0% 
   TOTAL 84 100%   
 
 
Figure 16. Likeliness of Monitors Helping Site Staff 
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Table 17 
Survey Respondents based on their Opinion about the Likeness of the Monitors Providing 
the Monitoring Visit Reports within a Short Time Frame 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very Likely 
 
 
15 
 
 
18.3% 
 
 
15 
 
 
18.3% 
 
Likely 
 
45 
 
54.9% 
 
60 
 
73.2% 
 
Not sure 
 
12 
 
14.6% 
 
72 
 
87.8% 
 
Unlikely 
 
Very Unlikely 
 
9 
 
1 
11.0% 
 
1.2% 
81 
 
82 
98.8% 
 
100.0% 
   TOTAL 82 100%   
 
 
Figure 17. Likeliness of Monitor Submitting the Monitoring Report within a Short Frame 
of Time 
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Table 18 
Survey Respondents referring to their Assessment about the Likeliness of Monitors 
Increasing the Work Load after the Completion of a Monitoring Visit 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very Likely 
 
 
30 
 
 
36.1% 
 
 
30 
 
 
36.1% 
 
Likely 
 
35 
 
42.2% 
 
65 
 
78.3% 
 
Not sure 
 
Unlikely 
 
8 
 
10 
 
9.7% 
 
12.0% 
 
73 
 
83 
 
88.0% 
 
100.0% 
 
Very Unlikely 0 0.0% 83 100.0% 
   TOTAL 83 100%   
 
 
Figure 18. Likeliness of Monitor Increasing the Work Load after a Monitoring Visit 
36.10%
42.20%
9.70%
12.00%
0.00%
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
45.00%
Very likely Likely Not sure Unlikely Very unlikely
Work Load Increase
58 
 
Table 19  
Survey Respondents based on their Judgment, Whether or Not the Quality of Data at the 
Site Depends upon the Monitor 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very much 
 
 
23 
 
 
27.7% 
 
 
23 
 
 
27.7% 
 
Moderately 
 
33 
 
39.8% 
 
56 
 
67.5% 
 
Not sure 
 
14 
 
16.9% 
 
70 
 
84.4% 
 
Minimally 
 
13 
 
15.6% 
 
83 
 
100.0% 
 
Does not reflect 
 
0 0.0% 83 100.0% 
   TOTAL 83 100%   
 
 
Figure 19. How Much the Quality Of Depends Upon Monitor 
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Table 20 
Survey Respondents based on their Assessment about the Helpfulness of Monitor in the 
Preparation of the Site for Audit or Inspection 
Response or Answer   Frequency Percent (%) Cumulative 
Frequency 
Cumulative 
Percent (%) 
 
Very much 
 
 
9 
 
 
12.5% 
 
 
9 
 
 
12.5% 
 
Moderately 
 
20 
 
27.8% 
 
29 
 
40.3% 
 
Not sure 
 
27 
 
37.5% 
 
56 
 
77.8% 
 
Minimally 
 
6 
 
8.3% 
 
62 
 
86.1% 
 
Not at all 
 
10 13.9% 72 100.0% 
   TOTAL 72 100%   
 
 
Figure 20. Helpfulness of Monitor in the Preparation of Audit or Inspection 
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Table 21  
Survey Responses Expressed by the Clinical Research Coordinators about the Quality of 
Monitoring in Clinical Trials Today as Compared to Five to Ten Years Ago 
Quality of monitoring has increased. 
Monitors are better prepared now. 
Quality of monitoring is very good. 
There is minimal improvement. 
All the monitors, I have dealt with are exceptional. 
More thorough, very particular about following GCP and keeping clean data. 
To me, the quality of monitoring in clinical trials has dramatically increased due to the 
electronic technology improvement as compared to 5-10 years ago. 
I mostly worked on NIH sponsored trials in basic science and there is no monitoring. I 
did work on one clinical trial for a drug company sponsor and the monitors are proficient. 
Study monitors can be inconsistent, especially when monitors change during the study. 
Compared to earlier, the consistency as well as overall quality has improved. 
The monitors I have worked with are very helpful in variety of ways. In particular, one 
monitor was very useful in determining what exactly the CRF’s were asking and 
educated me about some parameters and measures. Other monitor focuses on regulatory 
aspects and data review for accuracy, it is a great help in going to the sponsor to clarify 
any questions we have.  
It’s getting slightly better; the best monitor’s are the ones who have worked as a 
coordinator before. Most likely, they know where to look and what common things 
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should be corrected? 
Each monitor is different and most of them are well trained, knowledgeable and eager to 
help. 
No significant change in monitoring. 
Quality of monitoring is same and study monitoring depends on the complexity of the 
study that we are doing at the time of the monitoring visit. 
I think there are many new monitors who are not being trained or mentored as well as 
may have been the case 5-10 years ago. 
The quality of monitoring is not as good as 5-10 years ago. From my experiences, the 
monitors today are overwhelmed with too many sites or too many studies. 
I feel the quality of monitoring five years ago was much better than today. Today 
monitors are overwhelmed with workloads and they don’t really have the knowledge, 
some of them don’t have experience. 
I have seen a dramatic decrease in the experience and competence of monitors visiting 
my site during the past five years. In general, there are good monitors (certain CRO’s). 
Every monitor does things differently; they all want us to do things differently and don’t 
understand our IRB procedures as well as operating procedures. 
Varies by monitor. Monitors does not look at the data in the same way FDA does i.e., 
monitors focus on verifying data and do not look for inconsistencies. 
I feel the quality of monitoring has gone down because monitors are over worked. 
Monitoring quality has gone down because of the amount of sites and patients the 
monitors are responsible for. 
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Many companies are using in – house monitors, instead of a monitoring company and 
many in-house monitors are not versed with the correct monitoring procedures. 
Monitors change frequently during the course of the study and data requirements change 
from monitor to monitor. Some monitors have been the way too demanding of time or 
schedule and they don’t even understand that the coordinators have multiple studies or 
commitments. Either the sponsor needs to invest in training or increase number of 
monitors to avoid the huge turnover in industry studies. 
I found that monitors can be super helpful as well as experienced, at the same they make 
the things difficult. Really the quality of monitoring depends on the CRO. I found that 
every monitor is a bit different in their requests and style. Some are very easy to work 
with, while others are extremely difficult. It’s hard to answer their questions and make 
blanket statements. 60 to 70% of the monitors I have worked with are not helpful in 
cleaning up our regulatory and subject binders. 
The quality has gone down and monitors are responsible for too many protocols. The 
communication between CRO, sponsor and site is not good. On an average, we are seeing 
new monitors every six months. 
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Appendix A:  College of Health and Human Services Human Subjects Review 
Committee Approval Letter
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Appendix B: Survey Completion Request or Online Survey Consent Form or Email 
Survey 
Survey Title:  
 “Perceptions of Clinical Research Coordinators about Quality of Monitoring” 
Dear Clinical Research Coordinator: 
As a part of my master’s thesis, I am requesting your participation in a survey. 
You are being invited to complete this survey about quality of monitoring and 
major concerns/failings in the monitoring process from the perspective of clinical 
research coordinators. You were selected as a possible participant in my search for 
clinical research coordinators in Google and finally, I found your email contact in the 
website of the institution or company or clinical trial center that you are working. I 
strongly advise you do not use employer issued device (laptop, smart phones etc.) to 
respond to this survey. This research project is done by Praveen Krishna Movva from 
Eastern Michigan University.  
Your participation is voluntary and you may choose not to participate. If you 
decide to participate in this research survey, you may withdraw at anytime. Your 
participation and responses will be kept anonymous. There are no direct benefits 
associated with your participation, but your input is valued. There is no known risk 
involved in your participation. 
As a researcher I respect your rights to privacy and I hold in the utmost respect 
your responses to this survey and I will keep the survey results confidential. I am not 
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collecting any kind of personal identifiable information and personal health information 
during the course of this survey.  
The data will be collected via the online survey (Google Docs) and the results of 
the survey will be held by me. I will hold the data on a password protected personal 
laptop; there is no access to anyone. I will be protecting the laptop from theft and the 
word document containing email list for survey is both encrypted and password 
protected. The folder on my laptop (password protected) containing the results of the 
survey will be deleted upon the submission of the dissertation and the password protected 
document containing email list for survey will be deleted upon the completion of survey. 
I will be sending the survey to potential participants by using Google docs and the 
survey tool or document or form containing emails will be deleted forever upon the 
analysis of results. Privacy Policy of Google 
http://www.google.com/intl/en/policies/privacy/  
I have taken all reasonable measures to protect your identity and responses. 
However, email and the internet are not 100% secure, so it is also suggested that you 
clear the browser history to protect your privacy after completing the survey. 
The procedure for survey involves answering six demographics questions and 
fifteen questions about monitoring practices. The survey takes about 15 to 20 minutes to 
complete. 
Click on the following link to access the survey: 
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https://docs.google.com/spreadsheet/viewform?formkey=dHY4bkNzdGowbTRIVFJ0Tm
JTX3NkZUE6MQ 
By clicking on the link above, you are indicating that: 
• You have read above information. 
• You voluntarily agree to participate. 
• You are a clinical research coordinator. 
  I hope you will respond. This survey will be available for approximately two 
weeks to allow your participation. 
If you have any questions about the study, please contact Dr. Stephen A. Sonstein, 
Professor and Director of Clinical Research Administration, Eastern Michigan 
University, ssonstein@emich.edu. 
Thank you in advance for your participation! 
“This research protocol and informed consent document has been reviewed 
and approved by the Eastern Michigan University Human Subjects Review 
Committee for use from November 7 2012 to November 6 2013 (date). If you have 
questions about the approval process, please contact Dr. Gretchen Dahl Reeves 
(734-487-3236, Chair, College of Health and Human Services Human Subjects 
Review Committee, greeves@emich.edu). 
 
67 
 
Appendix C: Survey 
Survey Title:  
“Perceptions of Clinical Research Coordinators about Quality of Monitoring” 
Survey Questions include six demographic questions and 15 questions related to 
monitoring practices. 
Demographic Questions: 
1. What is the highest degree (or) level of education you have completed? 
• High School Graduate 
• Associate degree 
• Bachelor’s degree 
• Post-baccalaureate certificate 
• Master’s degree 
• Doctorate degree 
• Other(Please Specify) 
2. Which of the following best describes your educational background? 
• Nursing degree 
• Life Science degree (e.g. Pharmacy, Biochemistry, Biology) 
• Health Science degree (e.g. Clinical Laboratory Science, Physical 
Therapy) 
• Clinical Research degree 
• Other (Please Specify) 
3. Which of the following best describes your current work setting? 
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• Private Practice site 
• Academic site (University or Teaching Hospitals) 
• Community Hospital (Not Academically affiliated) 
• Site management organization (organizing a group of sites centrally to do 
studies) 
• Contract research organization (company or organization contracted by a 
pharmaceutical, medical device or biotechnology company to conduct 
clinical trials) 
• Other (please specify) 
4. Which of the following describes your current working pattern? (Select all that 
apply) 
• Medical device clinical trials 
• Pharmaceutical clinical trials 
• Investigator - initiated clinical trials 
• Government (or) Foundation – sponsored clinical trials 
• Other (please specify) 
5. About how long have you been working as a clinical research coordinator? 
• ≤ 2 years 
• > 2 to 5 years 
• > 5 to 10 years 
• > 10 years 
6. How many clinical trials have you participated in where you have interacted with 
a monitor? 
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A “monitor” is a professional who evaluates and analyzes clinical data and 
coordinates activities to ensure compliance with protocol and overall clinical 
objectives. Synonyms of monitor are clinical research monitor, clinical trials 
monitor, clinical research associate etc. 
• 1 to 5 
• 6 to 10 
• 11 to 20 
• > 20 
Monitoring Practices Questions: 
1. In general, how satisfied are you with the skill and competency of the monitors with 
whom you have interacted? 
• Very satisfied 
• Satisfied 
• Not sure 
• Dissatisfied 
• Very dissatisfied 
2. In general, how satisfied are you with the monitor’s level of understanding of the 
protocol and its requirements? 
• Very satisfied 
• Satisfied 
• Not sure 
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• Dissatisfied 
• Very dissatisfied 
3. In general, how satisfied are you with the review of the informed consent process 
conducted by the monitors with whom you have interacted? 
• Very satisfied 
• Satisfied 
• Not sure 
• Dissatisfied 
• Very dissatisfied 
4. In general, how satisfied are you with the review for protocol deviations conducted by 
the monitors with whom you have interacted? 
• Very satisfied 
• Satisfied 
• Not sure 
• Dissatisfied 
• Very dissatisfied 
5. In general, how satisfied are you with the review for accuracy and completeness of 
CRF entries and source documents against each other conducted by the monitors with 
whom you have interacted? 
• Very satisfied 
• Satisfied 
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• Not sure 
• Dissatisfied 
• Very dissatisfied 
6. In general, how satisfied are you with the review for reporting of adverse events 
conducted by the monitors with whom you have interacted? 
• Very satisfied 
• Satisfied 
• Not sure 
• Dissatisfied 
• Very dissatisfied 
7. In general, how satisfied are you with the review for accuracy of drug accountability 
records conducted by the monitors with whom you have interacted? 
• Very satisfied 
• Satisfied 
• Not sure 
• Dissatisfied 
• Very dissatisfied 
8. In general, how likely are the monitors with whom you have interacted to fail to review 
FDA and IRB approvals prior to study initiation?  
• Very Likely 
• Likely 
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• Not sure 
• Unlikely 
• Very Unlikely 
9. In general, how likely are the monitors with whom you have interacted to provide 
adequate technical support to the site staff about the study?  
• Very Likely 
• Likely 
• Not sure 
• Unlikely 
• Very Unlikely 
10. In general, how likely are the monitors with whom you have interacted to help the site 
staff in resolving the generated queries? 
• Very Likely 
• Likely 
• Not sure 
• Unlikely 
• Very Unlikely 
11. In general, how likely are the monitors with whom you have interacted to provide site 
monitoring reports in a short time frame after completing a monitoring visit? 
• Very Likely 
• Likely 
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• Not sure 
• Unlikely 
• Very Unlikely 
12. In general, how likely is it that there is an increase in work load following the 
completion of a monitoring visit? 
• Very Likely 
• Likely 
• Not sure 
• Unlikely 
• Very Unlikely 
13. In general, in a clinical study, how much do you believe the quality of the data at your 
site reflects upon the monitors with whom you have interacted? 
• Very much 
• Moderately 
• Not sure 
• Minimally 
• Does not reflect 
14. Has your site been audited or inspected in the past three years?  If so, has the monitor 
been helpful in preparation for the audit or inspection? 
• Very much 
• Moderately 
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• Not sure 
• Minimally 
• Not at all 
15. In general, what is your opinion about the quality of monitoring in clinical trials today 
as compared to 5-10 years ago? 
 
 
 
 
 
 
 
 
 
 
 
 
 
